A gut pattern measured before treatment marked who lost most on tirzepatide

More than one in four adults with obesity carry the same quiet mismatch: a stomach that empties fast while post-meal GLP-1 runs unexpectedly low, and hunger that climbs after eating anyway. Among the 61 who later started tirzepatide, the drug reduced total body weight by 21.5% at six months in that group, against 12.1% and 10.8% in the two groups whose biology lined up as expected.

Researchers at Mayo Clinic sorted 483 adults first, timing how fast a solid breakfast left the stomach and sampling GLP-1, peptide YY and cholecystokinin at 15, 45 and 90 minutes after the meal. Colon biopsies from a smaller set pointed the same way, with 45% lower glucagon expression and 50% lower peptide YY, and the gap in weight was visible by 3 months.

What the design cannot show is cause. The weight comparison was retrospective and rested on the 61 of 483 who happened to start the drug after being sorted, which is a thin base for a difference this large.

Any of this belongs with a qualified clinician who knows a person's health history, not with a label someone assigns themselves. What is still unknown is whether a timed scan and a morning of blood draws could ever be simple enough to sit in front of a prescription.

Read the full story at Medscape ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.